Trump administration targets Harvard’s patents

The Trump administration has escalated its dispute with Harvard University, initiating a "comprehensive review" of the university's federally funded research and the "march-in" process under the Bayh-Dole Act. This action, outlined in a letter from Commerce Secretary Howard Lutnick, could result in the federal government taking ownership of patents or granting third-party licenses for inventions if Harvard failed to meet disclosure requirements, potentially impacting the university's intellectual property rights and federal funding. While this marks a new front in ongoing tensions, including existing lawsuits and frozen funding, administration officials express optimism for a resolution, citing recent agreements with other universities.

Analysis

The Trump administration has significantly escalated its dispute with Harvard University by initiating a 'comprehensive review' of the institution's federally funded research programs and invoking the 'march-in' process under the Bayh-Dole Act. This action creates a direct and material risk to Harvard's intellectual property portfolio, as the federal government could potentially seize ownership of patents or grant third-party licenses if the university is found non-compliant with its contractual requirements. This new front adds to existing pressures, which include frozen federal funding and ongoing lawsuits. However, the situation is characterized by considerable uncertainty, as administration officials, including Education Secretary Linda McMahon, have publicly expressed optimism for a negotiated settlement, citing recent multimillion-dollar agreements with Columbia and Brown universities as a precedent. Signals from Harvard, such as the reported removal of certain student center websites, have been interpreted by the White House as goodwill gestures, indicating that back-channel negotiations are active despite the public escalation.

Key Decisions for Investors

• Investors with exposure to university endowments or related R&D ventures should recognize this as a key precedent for political risk impacting intellectual property rights and federal funding for academic institutions.
• Portfolio managers in sectors reliant on university research, such as biotech, should re-evaluate the political risk associated with their key academic partners, as this conflict demonstrates how funding and IP can become entangled in political disputes.
• Monitor the ongoing negotiations closely, as a potential settlement, similar to those with Columbia and Brown, would remove a significant overhang for Harvard and could be a positive signal for the broader higher education sector, while a failure to resolve the issue could set a negative precedent.